Good afternoon, and welcome to The Oncology Institute third quarter 2023 earnings conference call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. At this time, I would like to turn the conference over to Mark Hueppelsheuser, General Counsel at TOI. Thank you. You may begin. The press release announcing The Oncology Institute's results for the third quarter 2023 are available at the investor section of the company's website, theoncologyinstitute.com. A replay of this call will also be available on the company's website after the conclusion of this call. Before we get started, I would like to remind you of the company's safe harbor language. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For a further discussion of risks related to our business, see our filings with the SEC. This call will also discuss non-GAAP financial measures, such as Adjusted EBITDA. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC and available on our website. Joining me on the call today is our CEO, Dan Virnich, and our CFO, Mihir Shah. Following our prepared remarks, we'll open the call for your questions. With that, I'll turn the call over to Dan. Thank you, Mark. Good afternoon, everyone, and thank you for joining our third quarter call. I'm excited by the progress made this quarter and want to begin again by thanking our clinical staff and teammates for their remarkable contributions to furthering community-based oncology care for our patients every day and driving efficiency and innovation in our clinical model. Their collective performance has resulted in another impressive quarter of financial growth. Starting with the top line, I am very pleased to report that in the quarter we achieved 26% revenue growth compared to Q3 of 2022, supported by strong demand for our services. Importantly, our organic growth rate was 20% and our same-store sales growth was 17%. Our performance in the quarter demonstrates our ability to execute our strategy as we significantly grew the top line while improving profitability. Gross profit has improved sequentially since we announced the headwinds around IV drug m argins in Q1 2023. Adjusted EBITDA improved $1.4 million compared to Q3 2022. Through a concentrated effort to improve collection timeliness, we have seen improvement in our cash position and expect the improvement to continue in Q4 2023. As such, we expect to have adequate funds to fulfill our expansion objective in 2024 and remain on track to achieve positive adjusted EBITDA by end of next year. Now, I would like to highlight a few operational achievements since our last call. First, we hit a milestone by opening our 70th clinic. We anticipate 4 additional locations in Q4 in South Florida, and we'll use our expanded footprint in Broward and Dade counties to serve a new value-based contract, which I'll touch on shortly. Second, we added five physicians in the quarter, primarily in Florida, bringing our total provider count to 112. Third, a significant portion of our providers have successfully integrated Ambience, an AI-powered platform designed for clinical documentation, workflows, and enhancing the patient experience. As we continue to implement this tool, we aim to increase efficiency, optimize charge capture, and improve overall patient satisfaction, thus creating more capacity to accommodate our growing number of encounters. Fourth, we recently welcomed Jeremy Castle as our new Chief Operating Officer. Jeremy joins us with over 15 years of oncology industry experience and has a track record of driving growth and profitability for multi-state physician groups. Jeremy adds key strengths to our executive team on operational excellence, drug procurement strategy, and radiation oncology optimization, in addition to other skills. Lastly, with the recent appointment of Jessica Yankus as our new National Pharmacy Leader, we are now fully prepared to commence our 2024 operations with a strong focus on expanding our oral specialty drug business and enhancing margins through improved drug procurement strategies. Jessica brings valuable experience from AmerisourceBergen and her previous tenure at McKesson. Before I turn it over to Mihir to walk you through the financials, I want to provide an update on a significant milestone for TOI. Effective January 1, 2024, we entered into a full-risk capitated contract in South Florida with a national payer. The contract covers medical and radiation oncology services and is a milestone for TOI as our first direct-to-health plan capitation contract and will help us elevate the level of community-based oncology services for the patients we will treat through this partnership. This displaces the more common network model solution, which has been prevalent in Florida for many years, and we anticipate it to act as a catalyst for our continued growth as we demonstrate TOI's ability to deliver superior outcomes for both payers and patients. Now, I'll turn the call over to our CFO, Mihir Shah, to provide additional details on our third quarter financial results. Thank you, Dan, and good afternoon, everyone. As Dan shared, we are pleased with our third quarter results. Lives under contract are at 1.8 million. I would like to point out that the Q2 acquisition of 4 radiation o ncology clinics, we have now expanded radiation o ncology risk on 130,000 of our existing lives. Third quarter results: Consolidated revenue for Q3 2023 was $82 million, an increase of 26% compared to Q3 2022, and a 2% increase compared to Q2 2023. Gross profit in Q3 2023 was $16 million, an increase of 22% compared to Q3 2022. As mentioned in our Q2 call, we are seeing the results of our efforts to reduce overheads, which produced SG&A, including depreciation and amortization, of $30 million in Q3 2023, a decrease of 9.7% compared to Q3 2022. As a percentage of revenue, SG&A was 36.5% in the quarter, down 1,000 basis points from Q2 2023. Loss from operations for Q3 2023 was $14 million, a decrease of $6.2 million compared to Q3 2022. Net loss for Q3 2023 was $17 million, an increase of $14.7 million compared to Q3 2022, pr due to the change in the fair value of conversion options, derivative and earn-out liabilities, offset by an increase in gross profit. Adjusted EBITDA for Q3 2023 was -$5.4 million. Our adjusted EBITDA calculation does not add back provider startup costs, nor the consulting and legal fees associated with acquisition costs. Further details on how we define adjusted EBITDA can be found in our 10-K. Of note, starting 2022 Q4, we have modified our adjusted EBITDA calculation to now include cash compensation paid to our board of directors. As of the quarter end, our cash and cash equivalent balance was $27 million, and we have $60 million in investment, for a total of $87 million of cash and cash equivalents and investments. Now turning to guidance. We are reaffirming our full year 2023 guidance, and as a reminder, our revenue guidance range is $290 million-$320 million. This represents 15%-27% growth over 2022 revenue. Our gross profit guidance ranges from $60 million-$70 million, and our adjusted EBITDA guidance ranges from -$25 million to -$28 million. We continue to expect to end the year with 1.75 million-2 million lives under capitation. I will now turn it back over to Dan for some summary remarks. Thanks, Mihir. I want to close our call by providing an update on our progress towards meeting our 4 key strategic priorities, which I outlined during last quarter's call. Priority 1: eliminate cash burn. Q3 of 2023 was the lowest SG&A as a percentage of revenue we have seen since going public. This came after our restructure, which we completed in Q2, and we expect to achieve continued benefits in this key ratio as we scale through 2024. Priority 2: expanding patient lives under care through value-based partnership. We continue to drive margin improvement in our legacy markets through 3 key efforts. 1, ongoing expansion of capitated value-based partnership. We have several near-term pipeline opportunities which will expand our already dominant footprint as a value-based oncology provider in these markets. 2, expansion of radiation oncology. This provides enhanced continuity of care for patients requiring radiation, is a differentiator to pure play medical oncology practices, and drives margin on our fee-for-service business. Three, expansion of our clinical trials program. We are investing in infrastructure and technology to continue to drive randomization opportunities with the patients we serve in our legacy market. We are truly differentiated in our ability to bring trials to patient populations that are challenged with access to these potentially life-saving opportunities, and it is a key opportunity to add margin and manage risk for our payer partners. Priority number three: proving our new market. Our fully capitated agreement with a national payer in Florida is a historic milestone for TOI. We are excited to prove our model, which means dramatically lower costs for our payer partners while maintaining the highest standards of care. We believe follow-on growth opportunities in new markets using this new direct-to-health plan model will be a key driver of capitated growth for us in upcoming years.... Priority number four, leading the value-based oncology market. We remain the largest value-based oncology provider group in the country by lives served and revenue under value-based arrangement. We strongly believe we can continue to advance this lead by being an employer of choice for oncologists and driving innovation and community-based cancer care for the patients and payers that we serve, and look forward to continued focus on our top four priorities as we move forward. With that, we're now ready to take your question. Operator? Thank you. We will now be conducting a question -and- answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your questions from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. The first question comes from the line of Brian Tanquilut with Jefferies. Please go ahead. Hey, good afternoon, and thanks for taking the questions. It's Jack Slevin on for Brian. Wanted to start with the Florida cap contract. I know, sort of working towards that point has been a big part of the story since you all came public, so congrats on that front. Maybe just to, you know, get into the nuts and bolts right away, is there any way to size maybe the immediate opportunity in 2024, both from a revenue and gross profit perspective? And then, maybe any thoughts you could add in terms of, you know, what you can do with that contract to scale it over time as you continue to build out the footprint in Florida? Yeah, absolutely. I think the things that make this new capitated sort of contracting model really attractive to TOI, and thank you for the question, it's a really great one. Are one, it includes both Medical and Radiation Oncology capitation. Two, it's structured in a way that we will be working not just through our employed clinics, but with independent oncologists, which provides a number of benefits for TOI and for patients. And three, with this relationship, as well as several that are in the pipeline in 2024, because it's a national payer, if we do a fantastic job, which I'm confident we will, there should be follow-on expansion opportunities to build a relationship. It's a much larger pipeline than the sort of delegated medical group market, which has been our historic and very important, partners for the last 16 years. Got it. That's helpful. It's great color. And then maybe just stepping to the guidance for the full year based on the performance you've got to date. You know, it looks to me, both based on sort of the progress you've seen on the SG&A front, and sort of the way things have progressed, that we might be leaning towards the lower end of the gross profit range, to, to hit on, on EBITDA. Is that the right way to think about it, or can you give me sort of the moving pieces there, considering sort of that SG&A pathway that, that you guys have been able to, show some, some progress on? Sure, I can take that. I think we should be doing okay in the gross profit range. As you know, we went through some restructuring in our SG&A in the first half of this year, so I think that has some overhang that is not flowing through the bottom line for the full year yet. So our exit run rate would be much better than what you—what we see at for the full year for this year. Got it. That makes sense. And then last one for me, just looking at the cash flow, we've got, you know, almost $10 million of free cash burn in the quarter. Appreciate the comments you gave on the confidence in getting to EBITDA positive by the end of next year. Can you just walk me through sort of the moving pieces on the cash flow side to think about as you build that progression forward? Should it really just be sort of a step down of a few million less than the EBITDA path, or are there any, you know, larger items we should think about as you achieve, you know, sort of that progression on EBITDA? Thanks. Yeah. Yeah, excellent question, and good point about the $10 million ramp, or $10 million spend this quarter, which as you can see from the prior quarters, is close to $6 million-$7 million better than the prior quarter, but right? So this was our onset from second quarter to third quarter. We did put significant focus in the timeliness and accuracy of our collection, which we are also seeing benefit of. Taking that to next year, you are right, we should see most of the burn would be from negative Adjusted EBITDA, some CapEx, and potentially some acquisitions. So we do not see any other non-structured spend next year. Got it. Really helpful. Thanks again, and, congrats on the quarter. Thank you. Thank you. Thank you. There are no further questions at this time. I would now like to turn the floor over to Daniel Virnich for closing comments. Thanks so much, and thank you all for joining our earnings call today. In summary, I'm very pleased with our performance in the third quarter, and really looking forward to wrapping up the fourth quarter of this year. Again, this past quarter, we delivered, you know, strong growth year-over-year, expanded our gross margin and reduced SG&A, all of which is helping drive us towards our elimination of cash burn and path profitability towards the end of next year. We are seeing incredible growth opportunities in our pipeline, as outlined with our new relationship with we're starting in Florida and several additional opportunities, which we expect to announce in the upcoming quarters. Thank you all for joining today, and that concludes my comments. Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.